Asthma is a common disease affecting 350 million people worldwide, which is characterized
by airways inflammation and hyperreactivity. Historically diagnosis and treatment have been …

Asthma is a heterogenous disorder characterized by presence of different phenotypes and
endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk …

Background Current guidelines recommend tailoring of asthma management according to
disease control, which is largely defined by increased symptoms and deterioration in lung …

In asthma, clinical symptoms and lung function are insensitive in reflecting the underlying
airway inflammation, and monitoring of this process has only recently become available …

Fractioned exhaled nitric oxide (FeNO) is a noninvasive marker of inflammation in asthmatic
patients. FeNO can be used to monitor airway inflammation, but individual responses make …

Asthma is a pathologically heterogeneous disease, and the phenotype is characterized by
different types of airway inflammation. Exhaled nitric oxide (FENO) measurements are a …

Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2
inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together …

Fractional exhaled nitric oxide (FeNO) is a convenient, non-invasive method for the
assessment of active, mainly Th2-driven, airway inflammation, which is sensitive to treatment …

The current review aims to revisit literature on exhaled nitric oxide (FeNO) in asthma
phenotyping and management to clarify the utility of this test in clinical practice. It is …

Although not yet widely implemented, fraction of exhaled nitric oxide (FeNO) has emerged in
recent years as a potentially useful biomarker for the assessment of airway inflammation …